Gene-Editing Treatment For Sickle Cell Anemia Is Approved By FDA
A ground-breaking gene-editing therapy for sickle cell disease, a debilitating ailment that affects around 100,000 Americans, the majority of whom are people of color (POC), was authorized by the U.S. Food and Drug Administration (FDA) on Friday.
A ground-breaking gene-editing therapy for sickle cell disease, a debilitating ailment that affects around 100,000 Americans, the majority of whom are people of color (POC), was authorized by the U.S. Food and Drug Administration (FDA) on Friday.
What's Your Reaction?
